{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:08:53Z","timestamp":1761894533604},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2000,9,1]],"date-time":"2000-09-01T00:00:00Z","timestamp":967766400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Neurol"],"published-print":{"date-parts":[[2000,9]]},"DOI":"10.1007\/s11940-000-0042-x","type":"journal-article","created":{"date-parts":[[2007,6,4]],"date-time":"2007-06-04T14:16:45Z","timestamp":1180966605000},"page":"435-447","source":"Crossref","is-referenced-by-count":26,"title":["Beh\u00e7et\u2019s disease"],"prefix":"10.1007","volume":"2","author":[{"given":"Aksel","family":"Siva","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Izzet","family":"Fresko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"42_CR1","first-page":"1078","volume":"335","author":"International Study Group for Beh\u00e7et\u2019s Disease","year":"1990","unstructured":"International Study Group for Beh\u00e7et\u2019s Disease: Criteria for diagnosis of Beh\u00e7et\u2019s disease. Lancet 1990, 335:1078\u20131080.","journal-title":"Lancet"},{"key":"42_CR2","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1056\/NEJM199910213411707","volume":"341","author":"T Sakane","year":"1999","unstructured":"Sakane T, Takeno M, Suzuki N, Inaba G: Beh\u00e7et\u2019s disease. N Engl J Med 1999, 341:1284\u20131291. This recent article reviews current thoughts on the causation and pathophysiology of Beh\u00e7et\u2019s disease and outlines its clinical manifestations and their treatments.","journal-title":"N Engl J Med"},{"key":"42_CR3","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1212\/WNL.42.3.614","volume":"42","author":"B Wechsler","year":"1992","unstructured":"Wechsler B, Vidailhet M, Bousser MG, et al.: Cerebral venous sinus thrombosis in Beh\u00e7et\u2019s disease: long term follow-up of 25 cases. Neurology 1992, 42:614\u2013618. This article, in which a large series of patients with cerebral venous sinus thrombosis in Beh\u00e7et\u2019s disease is reported, is one of the earlier papers emphasizing that this form may represent a subtype of neurologic involvement seen in this disease.","journal-title":"Neurology"},{"key":"42_CR4","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s004150050205","volume":"245","author":"P Serdaroglu","year":"1998","unstructured":"Serdaroglu P: Beh\u00e7et\u2019s disease and the nervous system. J Neurol 1998, 245:197\u2013205. This article presents an overview of Beh\u00e7et\u2019s syndrome and reviews Neuro-Beh\u00e7et disease.","journal-title":"J Neurol"},{"key":"42_CR5","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1093\/brain\/122.11.2171","volume":"122","author":"G Akman-Demir","year":"1999","unstructured":"Akman-Demir G, Serdaroglu P, Tas\u00e7i B: Clinical patterns of neurological involvement in Beh\u00e7et\u2019s disease: evaluation of 200 patients. Brain 1999, 122:2171\u20132181. This study, in which the clinical features, evoked potentials, cerebrospinal fluid and imaging studies, and prognostic factors of BD with neurologic involvement are evaluated retrospectively, is the largest case series reported of its kind.","journal-title":"Brain"},{"key":"42_CR6","first-page":"115","volume-title":"Intravenous Immunoglobulins in the Treatment of Neurological Disorders","author":"A Siva","year":"2000","unstructured":"Siva A, Altintas A: Neuro-Beh\u00e7et Syndrome. In Intravenous Immunoglobulins in the Treatment of Neurological Disorders. Edited by Said G. London: Martin Dunitz Publishers; 2000: 115\u2013126."},{"key":"42_CR7","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1093\/brain\/122.11.2183","volume":"122","author":"D Kidd","year":"1999","unstructured":"Kidd D, Steuer A, Denman AM, Rudge P: Neurological complications in Beh\u00e7et\u2019s syndrome. Brain 1999, 122:2183\u20132194. This article describes the clinical, imaging, laboratory, and neurophysiologic features and prognostic factors in Beh\u00e7et\u2019s disease with neurologic involvement in a case series of 50 patients.","journal-title":"Brain"},{"key":"42_CR8","first-page":"1015","volume":"20","author":"N Ko\u00e7er","year":"1999","unstructured":"Ko\u00e7er N, Islak C, Siva A, et al.: CNS involvement in Neuro-Beh\u00e7et\u2019s syndrome: an MR study. Am J Neuroradiol 1999, 20:1015\u20131024. This article reports the imaging findings of CNS involvement in Beh\u00e7et\u2019s disease and emphasizes differential diagnosis in a large case series. The findings are also correlated with the current understanding of the pathophysiology of this form of neurologic involvement.","journal-title":"Am J Neuroradiol"},{"key":"42_CR9","first-page":"55","volume":"16","author":"MG Hadfield","year":"1997","unstructured":"Hadfield MG, Aydin F, Lippman HR, Sanders KM: Neuro-Beh\u00e7et\u2019s disease. Clin Neuropathol 1997, 16:55\u201360.","journal-title":"Clin Neuropathol"},{"key":"42_CR10","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/0002-9343(84)90753-8","volume":"76","author":"JD O\u2019Duffy","year":"1984","unstructured":"O\u2019Duffy JD, Robertson DM, Goldstein NP: Chlorambucil in the treatment of uveitis and meningoencephalitis of Beh\u00e7et\u2019s disease. Am J Med 1984, 76:75\u201384.","journal-title":"Am J Med"},{"key":"42_CR11","doi-asserted-by":"crossref","first-page":"627","DOI":"10.2214\/ajr.165.3.7645483","volume":"165","author":"RB Schwartz","year":"1995","unstructured":"Schwartz RB, Bravo SM, Klufas RA, et al.: Cyclosporine neurotoxicity and its relation to hypertensive neuropathy: CT and MR findings in 16 cases. Am J Roentgenol 1995, 165:627\u2013631. This article describes the clinical and radiologic findings in patients showing the neurotoxic effects of cyclosporine.","journal-title":"Am J Roentgenol"},{"key":"42_CR12","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/S0161-6420(99)90120-3","volume":"106","author":"S Kotake","year":"1999","unstructured":"Kotake S, Higashi K, Yoshikawa K, et al.: Central nervous system symptoms in patients with Beh\u00e7et disease receiving cyclosporine therapy. Ophthalmology 1999, 106:586\u2013589. This article reports on the higher incidence of neurotoxicity seen with the use of cyclosporine in Beh\u00e7et\u2019s disease.","journal-title":"Ophthalmology"},{"key":"42_CR13","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1468-1331.1996.tb00192.x","volume":"3","author":"G Akman-Demir","year":"1996","unstructured":"Akman-Demir G, Bahar S, Baykan-Kurt B, et al.: Intracranial hypertension in Beh\u00e7et\u2019s disease. Eur J Neurol 1996, 3:66\u201370.","journal-title":"Eur J Neurol"},{"key":"42_CR14","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/0002-9343(76)90166-2","volume":"61","author":"JD O\u2019Duffy","year":"1976","unstructured":"O\u2019Duffy JD, Goldstein NP: Neurologic involvement in seven patients with Beh\u00e7et\u2019s disease. Am J Med 1976, 61:170\u2013178.","journal-title":"Am J Med"},{"issue":"6","key":"42_CR15","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3349\/ymj.1997.38.6.401","volume":"38","author":"D Bang","year":"1997","unstructured":"Bang D: Treatment of Beh\u00e7et\u2019s disease. Yonsei Med J 1997, 38(6):401\u2013410. This article reviews the various agents and forms of treatment used in Beh\u00e7et\u2019s disease.","journal-title":"Yonsei Med J"},{"key":"42_CR16","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1016\/S0002-9270(98)00578-4","volume":"93","author":"S Kiziltas","year":"1998","unstructured":"Kiziltas S, Imery\u00fcz N, G\u00fcrcan T, et al.: Corticosteroid therapy augments gastroduodenal permeability to sucrose. Am J Gastroenterol 1998, 93:2420\u20132425.","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"42_CR17","first-page":"399","volume":"65","author":"E Aktulga","year":"1980","unstructured":"Aktulga E, Alta\u00e7 M, M\u00fc\u00fcft\u00fcoglu A, et al.: A double blind study of colchicine in Beh\u00e7et\u2019s disease. Haematologica 1980, 65(3):399\u2013402.","journal-title":"Haematologica"},{"key":"42_CR18","first-page":"S356","volume":"41","author":"S Yurdakul","year":"1998","unstructured":"Yurdakul S, Mat C, Ozyazgan Y, et al.: A double blind study of colchicine in Beh\u00e7et\u2019s syndrome (BS). Arthritis Rheum 1998, 41(suppl):S356.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"42_CR19","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1056\/NEJM199002013220501","volume":"322","author":"H Yazici","year":"1990","unstructured":"Yazici H, Pazarli H, Barnes CG, et al.: A controlled trial of azathioprine in Beh\u00e7et\u2019s syndrome. N Engl J Med 1990, 322(5):281\u2013285.","journal-title":"N Engl J Med"},{"issue":"4","key":"42_CR20","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1002\/art.1780400425","volume":"40","author":"V Hamuryudan","year":"1997","unstructured":"Hamuryudan V, Ozyazgan Y, Hizli N, et al.: Azathioprine in Beh\u00e7et\u2019s syndrome: effects on long-term prognosis. Arthritis Rheum 1997, 40(4):769\u2013774.","journal-title":"Arthritis Rheum"},{"key":"42_CR21","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1212\/WNL.46.6.1607","volume":"46","author":"C Confavreux","year":"1996","unstructured":"Confavreux C, Saddier P, Grimaud J, et al.: Risk of cancer from azathioprine therapy in multiple sclerosis: a case control study. Neurology 1996, 46:1607\u20131612.","journal-title":"Neurology"},{"issue":"3","key":"42_CR22","first-page":"136","volume":"20","author":"D Ben Ezra","year":"1988","unstructured":"Ben Ezra D, Cohen E, Chajek T, et al.: Evaluation of conventional therapy versus cyclosporin A in Beh\u00e7et\u2019s syndrome. Transplant Proc 1988, 20 (3 suppl 4):136\u2013143.","journal-title":"Transplant Proc"},{"key":"42_CR23","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1136\/bjo.76.4.241","volume":"4","author":"Y Ozyazgan","year":"1992","unstructured":"Ozyazgan Y, Yurdakul S, Yazici H, et al.: Low dose cyclosporin A versus pulsed cyclophosphamide in Beh\u00e7et\u2019s syndrome: a single masked trial. Br J Ophthalmol 1992, 4:241\u2013243.","journal-title":"Br J Ophthalmol"},{"key":"42_CR24","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/S0140-6736(89)92381-7","volume":"1","author":"K Masuda","year":"1989","unstructured":"Masuda K, Nakajima A, Urayama A, et al.: Double masked trial of cyclosporin versus colchicine and long term open study of cyclosporin in Beh\u00e7et\u2019s disease. Lancet 1989, 1:1093\u20131096.","journal-title":"Lancet"},{"key":"42_CR25","first-page":"603","volume-title":"Beh\u00e7et\u2019s Disease: Basic and Clinical Aspects","author":"SH Assad-Khalil","year":"1991","unstructured":"Assad-Khalil SH: Low dose of cyclosporin in Beh\u00e7et\u2019s disease: follow-up controlled study with emphasis on extraocular manifestations and Neuro-Beh\u00e7et\u2019s disease. In Beh\u00e7et\u2019s Disease: Basic and Clinical Aspects. Edited by O\u2019Duffy JD, K\u00f6kmen E. New York: Marcel Dekker; 1991:603\u2013612."},{"key":"42_CR26","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1136\/bjo.57.9.706","volume":"57","author":"MA Abdalla","year":"1973","unstructured":"Abdalla MA, Bahgat NE: Long lasting remission of Beh\u00e7et\u2019s disease after chlorambucil therapy. Br J Ophthalmol 1973, 57:706\u2013711.","journal-title":"Br J Ophthalmol"},{"issue":"2","key":"42_CR27","doi-asserted-by":"crossref","first-page":"2l7","DOI":"10.1002\/anr.1780320217","volume":"32","author":"JD Zelenski","year":"1989","unstructured":"Zelenski JD, Capraro JA, Holden D, Calabrase H: Central nervous system vasculitis in Beh\u00e7et\u2019s syndrome: angiographic improvement after therapy with cytotoxic agents. Arthritis Rheum 1989, 32(2):2l7\u2013220.","journal-title":"Arthritis Rheum"},{"key":"42_CR28","first-page":"575","volume-title":"Beh\u00e7et\u2019s Disease: Basic and Clinical Aspects","author":"EL Matteson","year":"1991","unstructured":"Matteson EL, O\u2019Duffy JD: Treatment of Beh\u00e7et\u2019s disease with chlorambucil. In Beh\u00e7et\u2019s Disease: Basic and Clinical Aspects. Edited by O\u2019Duffy JD, K\u00f6kmen E. New York: Marcel Dekker; 1991:575\u2013580."},{"key":"42_CR29","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1136\/bjo.74.6.353","volume":"74","author":"HH Tessler","year":"1990","unstructured":"Tessler HH, Jennings T: High dose short term chlorambucil for intractable sympathetic ophthalmia and Beh\u00e7et\u2019s disease. Br J Ophthalmol 1990, 74:353\u2013357.","journal-title":"Br J Ophthalmol"},{"key":"42_CR30","first-page":"1938","volume":"25","author":"JD O\u2019Duffy","year":"1998","unstructured":"O\u2019Duffy JD, Calamia K, Cohen S, et al.: Interferon alfa treatment of Beh\u00e7et\u2019s disease. J Rheumatol 1998, 25:1938\u20131944.","journal-title":"J Rheumatol"},{"key":"42_CR31","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1001\/archderm.134.8.1010","volume":"134","author":"CC Zouboulis","year":"1998","unstructured":"Zouboulis CC, Orfanos CE: Treatment of Adamantiades-Beh\u00e7et disease with systemic interferon alfa. Arch Dermatol 1998, 134:1010\u20131016.","journal-title":"Arch Dermatol"},{"issue":"5","key":"42_CR32","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1136\/bjo.82.5.488","volume":"82","author":"I Kotter","year":"1998","unstructured":"Kotter I, Eckstein AK, Stubiger N, Zierhut M: Treatment of ocular symptoms of Beh\u00e7et\u2019s disease with interferon alfa-2a: a pilot study. Br J Ophthalmol 1998, 82(5):488\u2013494.","journal-title":"Br J Ophthalmol"},{"issue":"11","key":"42_CR33","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1093\/rheumatology\/37.11.1148","volume":"37","author":"T Budak-Alpdogan","year":"1998","unstructured":"Budak-Alpdogan T, Demir\u00e7ay Z, Alpdogan O, et al.: Skin hyperreactivity of Beh\u00e7et\u2019s patients (pathergy reaction) is also positive in interferon alpha-treated chronic myeloid leukemia patients, indicating similarly altered neutrophil functions in both disorders. Br J Rheumatol 1998, 37(11):1148\u20131151.","journal-title":"Br J Rheumatol"},{"key":"42_CR34","first-page":"309","volume":"91","author":"T Kavano","year":"1996","unstructured":"Kavano T, Shigehira M, Uto H, et al.: Retinal complications during interferon therapy for chronic hepatitis C. Arch Ophthalmol 1996, 91:309\u2013313.","journal-title":"Arch Ophthalmol"},{"issue":"6","key":"42_CR35","doi-asserted-by":"crossref","first-page":"443","DOI":"10.7326\/0003-4819-128-6-199803150-00004","volume":"128","author":"V Hamuryudan","year":"1998","unstructured":"Hamuryudan V, Mat C, Saip S, et al.: Thalidomide in the treatment of the mucocutaneous lesions of the Beh\u00e7et syndrome. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998, 128(6):443\u2013450.","journal-title":"Ann Intern Med"},{"key":"42_CR36","first-page":"569","volume-title":"Beh\u00e7et\u2019s Disease: Basic and Clinical Aspects","author":"O Fain","year":"1991","unstructured":"Fain O, Huong Du LT, Wechsler B, et al.: Pulse cyclophosphamide in Beh\u00e7et\u2019s disease. In Beh\u00e7et\u2019s Disease: Basic and Clinical Aspects. Edited by O\u2019Duffy JD, K\u00f6kmen E. New York: Marcel Dekker; 1991:569\u2013573."},{"key":"42_CR37","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/art.1780240111","volume":"24","author":"P Merieux de","year":"1981","unstructured":"de Merieux P, Spitler LE, Paulus HE: Treatment of Beh\u00e7et syndrome with levamisole. Arthritis Rheum 1981, 24:64\u201367.","journal-title":"Arthritis Rheum"},{"key":"42_CR38","doi-asserted-by":"crossref","first-page":"891","DOI":"10.7326\/0003-4819-124-10-199605150-00005","volume":"124","author":"K Yasui","year":"1996","unstructured":"Yasui K, Ohta K, Kabayashi M, et al.: Successful treatment of BD with pentoxifylline. Ann Intern Med 1996, 124:891\u2013893.","journal-title":"Ann Intern Med"}],"container-title":["Current Treatment Options in Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-000-0042-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11940-000-0042-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-000-0042-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T20:56:43Z","timestamp":1559422603000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11940-000-0042-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,9]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2000,9]]}},"alternative-id":["42"],"URL":"https:\/\/doi.org\/10.1007\/s11940-000-0042-x","relation":{},"ISSN":["1092-8480","1534-3138"],"issn-type":[{"value":"1092-8480","type":"print"},{"value":"1534-3138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,9]]}}}